SCHEMBL1764630

SCHEMBL1764630

COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)cc3o2)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 4/20 1.00
CYP1B1 Q16678 4/20 1.00
AURKA O14965 1/20 0.86
KDR P35968 1/20 0.86
FLT3 P36888 1/20 0.86
AURKB Q96GD4 1/20 0.86
MEN1 O00255 2/20 0.79
KMT2A Q03164 2/20 0.79
ABCB1 P08183 2/20 0.79
TP53 P04637 1/20 0.79
MDM2 Q00987 1/20 0.79
ABCG2 Q9UNQ0 1/20 0.79
CYP1A2 P05177 2/20 0.73
HDAC6 Q9UBN7 2/20 0.73
KDM1A O60341 1/20 0.73
ABCC1 P33527 1/20 0.73
XDH P47989 1/20 0.73
IPMK Q8NFU5 1/20 0.73
IP6K2 Q9UHH9 1/20 0.73
OPRD1 P41143 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30082755 1.00 CYP1A1 (1.00) CYP1A1CYP1B1AURKAKDRFLT3
SCHEMBL8062995 0.94 CYP1A1 (0.88) CYP1A1CYP1B1AURKAKDRFLT3
Eupatorin SCHEMBL30334912 0.93 CYP1A1 (1.00) CYP1A1CYP1B1AURKAKDRFLT3
Eupatorin SCHEMBL555597 0.93 CYP1A1 (1.00) CYP1A1CYP1B1AURKAKDRFLT3
Eupatorin SCHEMBL29386042 0.93 CYP1A1 (1.00) CYP1A1CYP1B1AURKAKDRFLT3
SCHEMBL7127301 0.92 CYP1A1 (0.86) CYP1A1CYP1B1
SCHEMBL10031342 0.90 CYP1A1 (0.81) CYP1A1CYP1B1AURKAKDRFLT3
Sinensetin SCHEMBL621101 0.88 ABCB1 (1.00) CYP1A1CYP1B1AURKAKDRFLT3
Sinensetin SCHEMBL29549544 0.88 ABCB1 (1.00) CYP1A1CYP1B1AURKAKDRFLT3
Sinensetin SCHEMBL29700880 0.88 ABCB1 (1.00) CYP1A1CYP1B1AURKAKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240114939-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE FIRMENICH SA (CH) 2024-04-11 US claimed
EP-3703724-A1 EXTRACT OF ORTHOSIPHON STAMINEUS, FORMULATIONS, AND USES THEREOF NatureCeuticals Sdn. Bhd. (MY) 2020-09-09 EP claimed
US-20140039044-A1 Hydroxylated Polymethoxyflavone Compositions WLLGEN, INC. (US) 2014-02-06 US claimed
EP-2010194-A2 HYDROXYLATED POLYMETHOXYFLAVONE COMPOSITIONS Rutgers, The State University of New Jersey (US) 2009-01-07 EP claimed
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions WELLGEN, INC. 2007-11-29 US claimed
WO-2007109071-A2 HYDROXYLATED POLYMETHOXYFLAVONE COMPOSITIONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-09-27 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
EP-4251708-B1 METHOD FOR PRODUCING A HIGH-PHENOLIC-CONTENT BIOOIL THE UNIV OF NEW BRUNSWICK (CA) 2026-02-11 EP disclosed
US-20240114939-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE FIRMENICH SA (CH) 2024-04-11 US disclosed
US-20230365764-A1 METHOD FOR PRODUCING A HIGH-PHENOLIC-CONTENT BIOOIL THE UNIVERSITY OF NEW BRUNSWICK (CA) 2023-11-16 US disclosed
CN-113621622-B Citrus polymethoxy flavone biosynthesis gene and application thereof 华中农业大学 2023-10-27 CN disclosed
EP-4258899-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE Firmenich SA (CH) 2023-10-18 EP disclosed
WO-2003040077-A1 COMBRETASTATIN A-4 DERIVATIVES HAVING ANTINEOPLASTIC ACTIVITY CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-05-15 WO disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
US-6506792-B1 Breast and endometrial cancers are major causes of death in Western women. In particular, tumours in endocrine-dependent tissues, such as the breast and endometrium, occur most frequently in postmenopausal women at a time when the ovaries STERIX LIMITED (GB) 2003-01-14 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions PLIN5, FANCF, COXFA4 CYP1A1 175/4885CYP1B1 264/4885AURKA 3715/4885
US-20140039044-A1 Hydroxylated Polymethoxyflavone Compositions PLIN5, FANCF, COXFA4 CYP1A1 175/4885CYP1B1 264/4885AURKA 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.